Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases
Authors
Keywords
PI3K inhibitor, ETP-46321, Cancer therapeutics
Journal
INVESTIGATIONAL NEW DRUGS
Volume 31, Issue 1, Pages 66-76
Publisher
Springer Nature
Online
2012-05-23
DOI
10.1007/s10637-012-9835-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling
- (2010) E. Halilovic et al. CANCER RESEARCH
- The PI3K Pathway As Drug Target in Human Cancer
- (2010) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of Phosphoinositide-3 Kinase Pathway Inhibitors for Advanced Cancer
- (2010) James M. Cleary et al. Current Oncology Reports
- Using multiplexed regulation of luciferase activity and GFP translocation to screen for FOXO modulators
- (2009) Fabian Zanella et al. BMC CELL BIOLOGY
- Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression
- (2009) K. P. Hoeflich et al. CANCER RESEARCH
- Targeting the PI3K signaling pathway in cancer
- (2009) Kwok-Kin Wong et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Chemical Interrogation of FOXO3a Nuclear Translocation Identifies Potent and Selective Inhibitors of Phosphoinositide 3-Kinases
- (2009) Wolfgang Link et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
- (2009) F. I. Raynaud et al. MOLECULAR CANCER THERAPEUTICS
- Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
- (2009) M. L. Sos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
- (2008) Stephen D. Barrett et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging
- (2008) C. R. Schnell et al. CANCER RESEARCH
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Chemical Genetic Analysis of FOXO Nuclear-Cytoplasmic Shuttling by Using Image-Based Cell Screening
- (2008) Fabian Zanella et al. CHEMBIOCHEM
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†
- (2008) Adrian J. Folkes et al. JOURNAL OF MEDICINAL CHEMISTRY
- Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration
- (2008) Mariona Graupera et al. NATURE
- Class I PI3K in oncogenic cellular transformation
- (2008) L Zhao et al. ONCOGENE
- Drug discovery approaches targeting the PI3K/Akt pathway in cancer
- (2008) C Garcia-Echeverria et al. ONCOGENE
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More